NCAPH drives breast cancer progression and identifies a gene signature that predicts luminal a tumour recurrence.

ABSTRACT:

Background

Luminal A tumours generally have a favourable prognosis but possess the highest 10-year recurrence risk among breast cancers. Additionally, a quarter of the recurrence cases occur within 5 years post-diagnosis. Identifying such patients is crucial as long-term relapsers could benefit from extended hormone therapy, while early relapsers might require more aggressive treatment.

Methods

We conducted a study to explore non-structural chromosome maintenance condensin I complex subunit H's (NCAPH) role in luminal A breast cancer pathogenesis, both in vitro and in vivo, aiming to identify an intratumoural gene expression signature, with a focus on elevated NCAPH levels, as a potential marker for unfavourable progression. Our analysis included transgenic mouse models over

SUBMITTER: Mendiburu-Elicabe M 

PROVIDER: S-EPMC10859882 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature